Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

5
An evening walk down Dalal Street: MSP price hike gives a push to Indian markets; Sensex rallies over 250 points

2018-07-04 moneycontrol
The S&P BSE Sensex rallied over 200 points on Wednesday despite negative global cues. The Nifty50 reclaimed 10,700 levels and closed above its short-term moving averages such as 5-EMA, 13-EMA, as well as 50-EMA which is a bullish sign.
UNICHEMLAB KOHINOOR 539275 532899 BHRQY SRTRANSFIN 511218 532454 512559 532783 506690 KSCL SRRQY MSL 500570 BHARTIARTL TATAMOTORS DAAWAT TTM

0
Agri stocks soar up to 10% after government hikes minimum support price of kharif crops

2018-07-04 moneycontrol
Shares of agriculture-related stocks rose on Wednesday as investors were upbeat on government's decision to hike minimum support price.
512559 532783 KOHINOOR 539275 KSCL MSL 532899 DAAWAT

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

1
Monsanto rival Kaveri Seed seeks bigger pie of Indian seed market

2018-06-12 livemint
Mumbai: Kaveri Seed Co., which competes with Monsanto Co. to sell hybrid seeds in India, is seeking a bigger share of the food crop market to reduce dependence on cotton seed, its breadwinner. The company gets about 60% of revenue from cotton seed sales and the remainder from vegetable seeds and grains including paddy and corn. It aims to reverse the proportion in three years, enticed by profit margins that are almost double that of the cotton segment, executive director C.
KSCL MON 532899

1
Kaveri Seed: Eyes on results, buyback

2018-05-23 thehindubusinessline
The board of Kaveri Seed Company will meet on Thursday to consider the audited financial results for the quarter/year ended March 31, 2018. The board will also consider a proposal for buyback of the equity shares of the company. If the proposal is approved by the board, shareholders would be keen to know the price, issue size and mode of buyback (whether open market purchase or through tender route).
KSCL 532899 SBAZ

0
Ashoka Pte sells 6.60 lakh shares of Kaveri Seed Company

2018-05-19 moneycontrol
On May 18, 2018 Ashoka PTE sold 6,60,815 shares of Kaveri Seed Company at Rs 500.13 on the NSE.
KSCL 532899

0
BNP Paribas Arbitrage buys 4.15 lakh shares of Kaveri Seed Company

2018-03-29 moneycontrol
On March 28, 2018 BNP Paribas Arbitrage bought 4,15,000 shares of Kaveri Seed Company at Rs 485.50 on the BSE.
KSCL 532899

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...